Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Feb 13:9:1-11.
doi: 10.2147/ITT.S202006. eCollection 2020.

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update

Sandra Guallar-Garrido  1 , Esther Julián  1
Affiliations
Review

Bacillus Calmette-Guérin (BCG) Therapy for Bladder Cancer: An Update

Sandra Guallar-Garrido et al. Immunotargets Ther. .

Abstract

Physicians treating patients affected by nonmuscle-invasive bladder cancer (NMIBC) have been in shock during the last six years since manufacturing restrictions on the production of the first-option medicine, Mycobacterium bovis Bacillus Calmette-Guérin (BCG), have resulted in worldwide shortages. This shortage of BCG has led to a rethinking of the established treatment guidelines for the rationing of the administration of BCG. Some possible schedule modifications consist of a decrease in the length of maintenance treatment, a reduction in the dose of BCG in intravesical instillations or the use of different BCG substrains. All these strategies have been considered valuable in times of BCG shortage. In addition, the lack of availability of BCG has also led to the general recognition of the need to find new treatment options for these patients so that they are not dependent on a single treatment. Few alternatives are committed to definitively replacing BCG intravesical instillations, but several options are being evaluated to improve its efficacy or to combine it with other chemotherapeutic or immunotherapeutic options that can also improve its effect. In this article, we review the current state of the treatment with BCG in terms of all of the aforementioned aspects.

Keywords: alternative treatment; immunotherapy; mycobacteria; nonmuscle invasive.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Current alternative research for nonmuscle invasive bladder cancer treatment.
See this image and copyright information in PMC

References

    1. Morales A. BCG: a throwback from the stone age of vaccines opened the path for bladder cancer immunotherapy. Can J Urol. 2017;24(3):8788–8793. - PubMed
    1. Keller PM, Böttger EC, Sander P. Tuberculosis vaccine strain Mycobacterium bovis BCG Russia is a natural recA mutant. BMC Microbiol. 2008;8(1):120. doi:10.1186/1471-2180-8-120 - DOI - PMC - PubMed
    1. Liu J, Tran V, Leung AS, Alexander DC, Zhu B. Human vaccines BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin. 2009;5(2):70–78. doi:10.4161/hv.5.2.7210 - DOI - PubMed
    1. Zhang W, Zhang Y, Zheng H, et al. Genome sequencing and analysis of BCG vaccine strains. PLoS One. 2013;8:8. doi:10.1371/journal.pone.0071243 - DOI - PMC - PubMed
    1. Noguera-Ortega E, Julián E. Mycobacteria-derived agents for the treatment of urological and renal cancers. Mycobacterium - Res Dev. 2018;305–324. doi:10.5772/intechopen.69659 - DOI